These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10220615)

  • 21. Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.
    Dunn CJ; Foster RH
    Pharmacoeconomics; 1999 Dec; 16(6):711-41. PubMed ID: 10724797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economics of coronary stenting and GPIIb/IIIa blockade.
    Weintraub WS
    Eur Heart J; 2001 Aug; 22(16):1366-8. PubMed ID: 11482914
    [No Abstract]   [Full Text] [Related]  

  • 23. Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?
    Cole JH; Weintraub WS
    Circulation; 2003 Dec; 108(23):2831-3. PubMed ID: 14662689
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effectiveness analysis of abciximab: a Canadian hospital perspective.
    Zed PJ; Frighetto L; Sunderji R; Marra CA
    Ann Pharmacother; 1998 May; 32(5):536-42. PubMed ID: 9606473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abciximab therapy in percutaneous intervention: economic issues in the United States.
    Goklaney AK; Murphy JD; Hillegass WB
    Eur Heart J; 1998 Apr; 19 Suppl D():D52-8. PubMed ID: 9597522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the use of abciximab in percutaneous coronary intervention.
    Iversen AZ
    Dan Med Bull; 2011 Aug; 58(8):B4312. PubMed ID: 21827726
    [No Abstract]   [Full Text] [Related]  

  • 27. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.
    van Hout BA; Bowman L; Zelinger DJ; Simoons ML
    Am Heart J; 1998 Apr; 135(4):S98-106. PubMed ID: 9539500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abciximab and percutaneous coronary intervention: new indications. Medium-term benefit.
    Prescrire Int; 2000 Apr; 9(46):36-8. PubMed ID: 11503782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Percutaneous revascularization for unstable angina in the elderly.
    Hirsch H; Lazar J; Marzo KP; Steingart RM
    Coron Artery Dis; 2000 Jun; 11(4):315-22. PubMed ID: 10860174
    [No Abstract]   [Full Text] [Related]  

  • 30. [The role of abciximab in the prevention of the acute thrombotic complications of coronary angioplasty].
    Mesquita A; Baptista J; Almeida M; Ferreira J; Machado F; Palos L; Silva A; Seabra-Gomes R
    Rev Port Cardiol; 1997 Dec; 16(12):1031-5. PubMed ID: 9522626
    [No Abstract]   [Full Text] [Related]  

  • 31. Elective or selective use of abciximab?
    Butler R; Samani NJ
    Lancet; 2000 Feb; 355(9205):755. PubMed ID: 10703832
    [No Abstract]   [Full Text] [Related]  

  • 32. Will blocking the platelet save the diabetic?
    King SB; Mahmud E
    Circulation; 1999 Dec 21-28; 100(25):2466-8. PubMed ID: 10604881
    [No Abstract]   [Full Text] [Related]  

  • 33. Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands.
    van Hout BA; Simoons ML
    Eur Heart J; 1995 Nov; 16 Suppl L():81-5. PubMed ID: 8869024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R; Glick HA; Herrmann HC; Kimmel SE
    J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
    Gunasekara AP; Walters DL; Aroney CN
    Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Medico-economic evaluation of abciximab].
    Le Pen C; Bonastre J; Pinton P
    Ann Cardiol Angeiol (Paris); 1999 Jan; 48(1):80-6. PubMed ID: 12555363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
    Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML
    Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912
    [No Abstract]   [Full Text] [Related]  

  • 38. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA.
    Lenderink T; Boersma E; Heeschen C; Vahanian A; de Boer MJ; Umans V; van den Brand MJ; Hamm CW; Simoons ML;
    Eur Heart J; 2003 Jan; 24(1):77-85. PubMed ID: 12559939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study).
    Kini AS; Richard M; Suleman J; Perez N; Lee P; Fisher EA; Kamran M; Marmur JD; Sharma SK
    Am J Cardiol; 2002 Sep; 90(5):526-9. PubMed ID: 12208416
    [No Abstract]   [Full Text] [Related]  

  • 40. [Monoclonal antibodies in cardiology].
    Legrand V
    Rev Med Liege; 2009; 64(5-6):310-2. PubMed ID: 19642465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.